Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019031471) THERAPEUTIC AGENT FOR FATTY LIVER DISEASES AND THERAPEUTIC AGENT FOR ADIPOSITY
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2019/031471 International Application No.: PCT/JP2018/029496
Publication Date: 14.02.2019 International Filing Date: 06.08.2018
Chapter 2 Demand Filed: 28.02.2019
IPC:
A61K 31/403 (2006.01) ,A61K 31/198 (2006.01) ,A61K 31/216 (2006.01) ,A61K 31/223 (2006.01) ,A61K 31/235 (2006.01) ,A61K 31/245 (2006.01) ,A61K 31/341 (2006.01) ,A61K 31/538 (2006.01) ,A61K 31/55 (2006.01) ,A61P 1/16 (2006.01) ,A61P 3/04 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
40
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403
condensed with carbocyclic rings, e.g. carbazole
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
185
Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19
Carboxylic acids, e.g. valproic acid
195
having an amino group
197
the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
198
Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
21
Esters, e.g. nitroglycerine, selenocyanates
215
of carboxylic acids
216
of acids having aromatic rings, e.g. benactizyne, clofibrate
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
21
Esters, e.g. nitroglycerine, selenocyanates
215
of carboxylic acids
22
of acyclic acids, e.g. pravastatin
223
of alpha-amino acids
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
21
Esters, e.g. nitroglycerine, selenocyanates
215
of carboxylic acids
235
having an aromatic ring attached to a carboxyl group
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
21
Esters, e.g. nitroglycerine, selenocyanates
215
of carboxylic acids
235
having an aromatic ring attached to a carboxyl group
24
having an amino or nitro group
245
Amino benzoic acid types, e.g. procaine, novocaine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
34
having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
341
not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
535
having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
5375
1,4-Oxazines, e.g. morpholine
538
ortho- or peri-condensed with carbocyclic ring systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
55
having seven-membered rings, e.g. azelastine, pentylenetetrazole
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1
Drugs for disorders of the alimentary tract or the digestive system
16
for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
04
Anorexiants; Antiobesity agents
Applicants:
国立大学法人広島大学 HIROSHIMA UNIVERSITY [JP/JP]; 広島県東広島市鏡山一丁目3番2号 3-2, Kagamiyama 1-chome, Higashihiroshima-shi, Hiroshima 7398511, JP
学校法人東京薬科大学 TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCES [JP/JP]; 東京都八王子市堀之内1432-1 1432-1, Horinouchi, Hachioji-shi, Tokyo 1920392, JP
国立大学法人 東京大学 THE UNIVERSITY OF TOKYO [JP/JP]; 東京都文京区本郷七丁目3番1号 3-1, Hongo 7-chome, Bunkyo-ku, Tokyo 1138654, JP
Inventors:
浅野 知一郎 ASANO, Tomoichiro; JP
中津 祐介 NAKATSU, Yusuke; JP
伊藤 久央 ITO, Hisanaka; JP
岡部 隆義 OKABE, Takayoshi; JP
Agent:
永島 孝明 NAGASHIMA, Takaaki; JP
若山 俊輔 WAKAYAMA, Shunsuke; JP
Priority Data:
2017-15280707.08.2017JP
Title (EN) THERAPEUTIC AGENT FOR FATTY LIVER DISEASES AND THERAPEUTIC AGENT FOR ADIPOSITY
(FR) AGENT THÉRAPEUTIQUE CONTRE LA STÉATOSE HÉPATIQUE, ET AGENT THÉRAPEUTIQUE CONTRE L'OBÉSITÉ
(JA) 脂肪性肝疾患の治療剤及び肥満症の治療剤
Abstract:
(EN) [Problem] The purpose of the invention is to develop a novel therapeutic drug for fatty liver diseases such as NASH and NAFLD. [Solution] The invention provides a therapeutic or prophylactic agent for fatty liver diseases that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The invention also provides a therapeutic or prophylactic agent for adiposity that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
(FR) L'invention a pour objet de fournir un nouvel agent thérapeutique contre la stéatose hépatique type stéatohépatite non alcoolique (NASH), la stéatose hépatique non alcoolique (NAFLD), ou similaire. Plus précisément, l'invention fournit un agent thérapeutique ou un agent de prévention de la stéatose hépatique qui comprend en tant que principe actif un composé représenté par la formule (I) suivante ou un sel pharmaceutiquement acceptable de celui-ci. Enfin, l'invention fournit un agent thérapeutique ou un agent de prévention de l'obésité qui comprend en tant que principe actif un composé représenté par la formule (I) suivante ou un sel pharmaceutiquement acceptable de celui-ci.
(JA) 【課題】NASHやNAFLD等の脂肪性肝疾患に対する新規の治療薬を開発することを目的とする。 【解決手段】本発明は、次の式(I)で表される化合物又はその薬学的に許容される塩を有効成分として含有する、脂肪性肝疾患の治療剤又は予防剤を提供する。また、本発明は、次の式(I)で表される化合物又はその薬学的に許容される塩を有効成分として含有する、肥満症の治療剤又は予防剤を提供する。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)